Clinical Trial Update: Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating carboplatin, paclitaxel, bevacizumab, and vorinostat for advanced non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Paraplatin (Carboplatin)
• Taxol (paclitaxel)
• Zolinza (vorinostat)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED